John Wiley & Sons Biomarkers in Cancer Screening and Early Detection Cover Prepared by world leaders on this topic, Biomarkers in Cancer Screening and Early Detection offers a.. Product #: 978-1-118-46880-7 Regular price: $139.25 $139.25 Auf Lager

Biomarkers in Cancer Screening and Early Detection

Srivastava, Sudhir (Herausgeber)

Translational Oncology


1. Auflage August 2017
320 Seiten, Hardcover

ISBN: 978-1-118-46880-7
John Wiley & Sons

Jetzt kaufen

Preis: 149,00 €

Preis inkl. MwSt, zzgl. Versand

Weitere Versionen


Prepared by world leaders on this topic, Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and use in developing personalized cancer treatment.
* Offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers
* Provides immediately actionable information - and hopefully also inspiration - to move discovery and clinical application forward
* Offers vital knowledge to help develop personalized cancer treatment for individual patients with specific cancers

List of Contributors, ix

Preface, xiii

Part I Foundations of Biomarker Research

1 Nuts and Bolts of Biomarker Research, 3
Sharmistha Ghosh and Sudhir Srivastava

2 Cancer Genome Methylation: Biology, Biomarker and Therapeutic Opportunities, 16
Shashwat Sharad, Taduru Sreenath, Shiv Srivastava, and Albert Dobi

3 MicroRNA Biomarkers for Early Detection of Cancer, 27
WendyWang, Matthew R Young, and Sudhir Srivastava

4 Inflammation and Cancer, 37
Pamela L Beatty, Sandra Cascio, and Olivera J Finn

5 Exosomes: A Valuable Biomedical Tool in Biomarker Discovery and Development, 50
Jocelyn Lee, Sharmistha Ghosh, and Sudhir Srivastava

6 Epithelial-to-Mesenchymal Transition (EMT): Clinical Implications, 64
Elisa CWoodhouse and Suresh Mohla

Part II State-of-the-Science in Organ-Specific Biomarker Research

7 Breast Cancer, 77
Benjamin A Katchman, Christos Patriotis, and Karen S Anderson

8 Ovarian Cancer, 93
Christos Patriotis, Archana Simmons, Karen H Lu, Robert C Bast, Jr, and Steven J Skates

9 Esophageal Cancer Biomarkers, 104
Yanxin Luo, Kishore Guda, SanfordD Markowitz, Amitabh Chak, Andrew M Kaz, andWilliam M Grady

10 Predictive Biomarkers for Therapy in Adenocarcinoma of the Upper Digestive Tract, 118
Heath D Skinner, Qiongrong Chen, Elena Elimova, RoopmaWadhwa, Shumei Song, and Jaffer A Ajani

11 Pancreatic Cancer, 130
Sam CWang and Peter J Allen

12 Colon Cancer, 141
Paul DWagner

13 Prognostic and Predictive Biomarkers for Colorectal Cancer, 151
Upender Manne, Balananda-Dhurjati Kumar Putcha, Temesgen Samuel, and Sudhir Srivastava

14 Early Detection of Lung Cancer, 163
Mohamed Hassanein, Melinda C Aldrich, Stephen A Deppen, Karl E Krueger, Eric L Grogan, and Pierre P Massion

15 Commonalities in Lung Cancer and COPD, 185
MalgorzataWojtowicz and Eva Szabo

16 Prostate Cancer, 197
Jacob Kagan, Ian M Thompson, and DanielWChan

Part III Biomarkers, Screening and Precision Health: Implications for Public Health

17 Improving the Clinical Validity of Biomarker Research in Cancer Detection, 209
David F Ransohoff

18 Cancer Overdiagnosis, Ramifications and Research Strategies, 220
Barbara K Dunn and Barnett S Kramer

19 Predictive Markers and Driver Genes From Treatment Trials: Potential Utility For Early Diagnosis, 231
Brian S Sorg, Sarfraz Memon, Kelly Y Kim, Aniruddha Ganguly, Tracy Lively, James Tricoli, Magdalena Thurin, Lokesh Agrawal, Tawnya C McKee, Barbara A Conley, and J Milburn Jessup

20 Statistical Consideration in Predictive and Prognostic Markers, 245
Fei Ye and Yu Shyr

21 Clinical Validation of Molecular Biomarkers in Translational Medicine, 256
Harry B Burke and William E Grizzle

22 Cancer Biomarker Assays: Performance Standards, 267
Anna K Fuzery and Daniel W Chan

23 Bioethics and Cancer Biomarker Research, 277
Nathan Nobis, William Grizzle, and Stephen Sodeke

24 Colon Cancer Screening, 283
Molly Perencevich, Jennifer Inra, and Sapna Syngal
Sudhir Srivastava, Ph.D., MPH

Senior Scientific Officer, Chief, Cancer Biomarkers Research Group

Division of Cancer Prevention, National Cancer Institute

Bethesda, MD, USA

Dr Srivastava has received many honors and awards and is a member of several scientific committees (AJCC, AACR, All Ireland-NCI Consortium). Dr. Srivastava is a founding member of HUPO (Human Proteome Organisation) and has actively participated in the Plasma Proteome and the Liver Proteome Projects. He is the principal architect of the NCI's Early Detection Research Network and Alliance of Glycobiologists for the Detection of Cancer and Cancer Risk. He supported the first-ever joint meetings of EDRN-HUPO PPP and Proteomics Jamboree, and recently-held the US-Japan meeting on Glycolic. He has published more than 200 research papers, review articles and commentaries in peer reviewed journals. HJ has edited two other books: Informatics in Proteomics and Nanotechnology for Cancer Detection and Diagnosis (forthcoming). He is also the Editor-in Chief of the journals Disease Markers and Cancer Biomarkers.

S. Srivastava, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA